Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H5 AC-Anhui mRNA-LNP Vaccine in Healthy Adults
NCT07019883Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H5 AC-Anhui and H5 Astrakhan RNA Vaccine in Avian Influenza (AI) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events of Special Interest, Medically Attended Adverse Events and 6 more. Started Jun 2025; status: completed.
02
Drugs
H5 AC-AnhuiH5 Astrakhan RNA Vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT07019883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019883.